Histiocytic Sarcoma of the Eyelid: An Uncommon Presentation of a Rare Neoplasm.

Ophthalmic Plast Reconstr SurgJun 4, 2026 (epub)

Grace Baldwin, Lisa Y Lin, Anna M Stagner et al.

✦ AI-curated · Sources linked

Case in brief

An 80-year-old man presented with a rapidly enlarging lesion of the left lower eyelid over 4 months. Shave biopsy showed histologic and immunophenotypic features most consistent with morphologically low-grade histiocytic sarcoma. Complete excision, including additional 2 mm peripheral and deep margins, achieved clear margins. Systemic evaluation and whole-body imaging found no metastases or associated malignancy. Radiation was deferred in favor of close observation every 3 months; at 2 years after presentation, there was no evidence of recurrence.

What made this case unusual

The tumor presented in eyelid skin, an exceptionally uncommon site for histiocytic sarcoma; the abstract notes only one prior eyelid-skin case.

Diagnostic / clinical pearl

A rapidly growing eyelid lesion can represent histiocytic sarcoma; biopsy with histologic and immunophenotypic assessment established the diagnosis in this case.

Source

Published in Ophthalmic Plast Reconstr Surg. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Ophthalmology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.